261 related articles for article (PubMed ID: 26297875)
21. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
22. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
23. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation.
Cohen R; Varon E; Doit C; Schlemmer C; Romain O; Thollot F; Béchet S; Bonacorsi S; Levy C
Vaccine; 2015 Sep; 33(39):5118-26. PubMed ID: 26271823
[TBL] [Abstract][Full Text] [Related]
24. Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
Hu T; Done N; Petigara T; Mohanty S; Song Y; Liu Q; Lemus-Wirtz E; Signorovitch J; Sarpong E; Weiss T
BMC Infect Dis; 2022 Mar; 22(1):294. PubMed ID: 35346092
[TBL] [Abstract][Full Text] [Related]
25. Ambulatory Visits for Otitis Media before and after the Introduction of Pneumococcal Conjugate Vaccination.
Kawai K; Adil EA; Barrett D; Manganella J; Kenna MA
J Pediatr; 2018 Oct; 201():122-127.e1. PubMed ID: 29958675
[TBL] [Abstract][Full Text] [Related]
26. All-cause pneumonia in children after the introduction of pneumococcal vaccines in the United Kingdom: A population-based study.
Lau WCY; Bielicki J; Tersigni C; Saxena S; Wong ICK; Sharland M; Hsia Y
Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):821-829. PubMed ID: 30993835
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media.
Dagan R; Van Der Beek BA; Ben-Shimol S; Pilishvili T; Givon-Lavi N
Clin Infect Dis; 2021 Aug; 73(4):650-658. PubMed ID: 33507250
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
29. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
[TBL] [Abstract][Full Text] [Related]
30. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
Regev-Yochay G; Katzir M; Strahilevitz J; Rahav G; Finn T; Miron D; Maor Y; Chazan B; Schindler Y; Dagan R;
Vaccine; 2017 Apr; 35(18):2449-2456. PubMed ID: 28342668
[TBL] [Abstract][Full Text] [Related]
31. Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.
Gidding HF; Sheridan S; Fathima P; Moore HC; Liu B; McIntyre PB; Palmu AA;
Pediatr Infect Dis J; 2019 Aug; 38(8):860-865. PubMed ID: 30985507
[TBL] [Abstract][Full Text] [Related]
32. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
Weil-Olivier C; van der Linden M; de Schutter I; Dagan R; Mantovani L
BMC Infect Dis; 2012 Sep; 12():207. PubMed ID: 22954038
[TBL] [Abstract][Full Text] [Related]
33. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
[TBL] [Abstract][Full Text] [Related]
34. The rise and fall of pneumococcal serotypes carried in the PCV era.
Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
[TBL] [Abstract][Full Text] [Related]
35. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
[TBL] [Abstract][Full Text] [Related]
36. The effect of pneumococcal conjugate vaccines on incidence and microbiology associated with complicated acute otitis media.
Laursen BB; Danstrup CS; Hoffmann S; Nørskov-Lauritsen N; Christensen ALB; Ovesen T
Int J Pediatr Otorhinolaryngol; 2017 Oct; 101():249-253. PubMed ID: 28964304
[TBL] [Abstract][Full Text] [Related]
37. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review.
Taylor S; Marchisio P; Vergison A; Harriague J; Hausdorff WP; Haggard M
Clin Infect Dis; 2012 Jun; 54(12):1765-73. PubMed ID: 22423134
[TBL] [Abstract][Full Text] [Related]
38. Studying PCV impact on clinical presentation of otitis media helps to understand its pathogenesis.
Ben-Shimol S; Givon-Lavi N; Leibovitz E; Greenberg D; Dagan R
Vaccine; 2019 Jan; 37(1):1-6. PubMed ID: 30497832
[TBL] [Abstract][Full Text] [Related]
39. Influence of pneumococcal conjugate vaccines on acute otitis media in Japan.
Sasaki A; Kunimoto M; Takeno S; Sumiya T; Ishino T; Sugino H; Hirakawa K
Auris Nasus Larynx; 2018 Aug; 45(4):718-721. PubMed ID: 29102419
[TBL] [Abstract][Full Text] [Related]
40. Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US.
Shea KM; Weycker D; Stevenson AE; Strutton DR; Pelton SI
Vaccine; 2011 Oct; 29(45):8042-8. PubMed ID: 21871518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
